Skip to main content
European Commission logo print header

Design and development of novel inhibitor compounds of hepatitis c ires (internal ribosome entry site ) function

Objectif

HVC is a growing European medical problem here there is no effective long-term therapy. Mostly fatal, this infectious disease may be chronically carried by 5 million Europeans placing a huge burden on medical services and resources. Novel and effective antiviral therapies are therefore urgently needed. We use rational drug design to develop new drugs to combat HCV at a critical stage in its life cycle. Our dugs fit a specific target in the RNA structure, freezing its shape, it is no longer able to bind its native protein, and thus viral replication is inhibited. We will determine the 3D structure of the RNA target, design and make novel drugs, develop assays to measure inhibition of RNA function, and make through iterative cycles lead molecules. In collaboration withal pharmaceutical partner such drugs would be entered into a clinical evaluation programme. This research will benefit Europeans by producing novel therapies to this debilitating and often fatal disease.

Appel à propositions

Data not available

Régime de financement

CSC - Cost-sharing contracts

Coordinateur

VERNALIS (CAMBRIDG) LIMITED
Contribution de l’UE
Aucune donnée
Adresse
Granta Park, Abington
CB1 6GB CAMBRIDGE
Royaume-Uni

Voir sur la carte

Coût total
Aucune donnée

Participants (4)